Matthias Kirsch

Matthias Kirsch

Auto-generated profile, based on publicly available information

Matthias Kirsch

Department of Cardiac Surgery, Lausanne University Hospital (CHUV) , Lausanne

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2020 in Journal of Orthopaedics
Verified
Journal Article
Closed access
BFBrendan J. Farley
Brendan J. Farley
BSBrian M. Shear
Brian M. Shear
VLVivian Lu
Vivian Lu
KWKyla Walworth
Kyla Walworth
KGKevin Gray
Kevin Gray
JCJohn M. Clements
John M. Clements

28 May 2024 in Interdisciplinary CardioVascular and Thoracic Surgery
Verified
Journal Article
Open access
FDFilip Dulguerov
Filip Dulguerov
TATamila Abdurashidova
Tamila Abdurashidova
ECemeline christophel
emeline christophel
LILucian Ion
Lucian Ion
ZGZiyad Gunga
Ziyad Gunga
MKMatthias Kirsch
Matthias Kirsch
OBJECTIVES: The choice of the cardiac preservation solution for myocardial protection at time of heart procurement remains controversial and uncertainties persist regarding its effect on the early and midterm heart transplantation (HTx) outcomes. We retrospectively compared our adult HTx performed with 2 different solutions, in terms of hospital mortality, mid-term survival, inotropic score, primary graft dysfunction and rejection score. METHODS: From January 2009 to December 2020, 154 consecutive HTx of adult patients, followed up in pre- and post-transplantation by 2 different tertiary centres, were performed at the University Hospital of Lausanne, Switzerland. From 2009 to 2015, the cardiac preservation solution used was exclusively St-Thomas, whereafter an institutional decision was made to use HTK-Custodiol only. Patients were classified in 2 groups accordingly. RESULTS: There were 75 patients in the St-Thomas group and 79 patients in the HTK-Custodiol group. The 2 groups were comparable in terms of preoperative and intraoperative characteristics. Postoperatively, compared to the St-Thomas group, the Custodiol group patients showed significantly lower inotropic scores [median (interquartile range): 35.7 (17.5–60.2) vs 71.8 (31.8–127), P < 0.001], rejection scores [0.08 (0.0–0.25) vs 0.14 (0.05–0.5), P = 0.036] and 30-day mortality rate (2.5% vs 14.7%, P = 0.007) even after adjusting for potential confounders. Microscopic analysis of the endomyocardial biopsies also showed less specific histological features of subendothelial ischaemia (3.8% vs 17.3%, P = 0.006). There was no difference in primary graft dysfunction requiring postoperative extracorporeal membrane oxygenation. The use of HTK-Custodiol solution significantly improved midterm survival (Custodiol versus St-Thomas: hazard ratio = 0.20, 95% confidence interval: 0.069–0.60, P = 0.004). CONCLUSIONS: This retrospective study comparing St-Thomas solution and HTK-Custodiol as myocardial protection during heart procurement showed that Custodiol improves outcomes after HTx, including postoperative inotropic score, rejection score, 30-day mortality and midterm survival.